PER® Miami Breast Cancer Conference | Conference

Dr Mahtani on Unique Challenges Women in Oncology Experience During Career Transitions

March 19th 2024

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care

March 18th 2024

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

McCann on the Intersection of Mentorship, Multidisciplinary Care, and Career Aspirations as a Woman in Oncology

March 18th 2024

Kelly E. McCann, MD, PhD, discusses her career journey and evolving career aspirations as a woman in oncology.

Navigating Career Crossroads: Insights from Hope Rugo’s Journey as a Woman in Oncology

March 15th 2024

Hope S. Rugo, MD, draws on her own journey as a woman in oncology to provide insights on navigating career transitions and building support networks.

Graff Highlights the Importance of Perseverance and Self-Advocacy as a Woman in Oncology

March 15th 2024

Stephanie L. Graff, MD, shares her journey to becoming an oncologist, advice for work-life balance, and ways to confront gender bias in medicine.

Dr Plichta on Areas of Interest for Genetic Testing Research in Breast Cancer

March 14th 2024

Jennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.

Dr Hwang on the Potential Use of Multicancer Early Detection Tests in Breast Cancer Screening

March 14th 2024

Shelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.

Dr Jimenez on the Radiation Treatment Paradigm in Breast Cancer

March 13th 2024

Rachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.

Dr Graff on the Trajectory of Her Career in Breast Cancer

March 11th 2024

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Dr Rugo on Challenges Faced as a Woman in Oncology

March 11th 2024

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

MRD Testing Presents Challenges and Opportunities in Breast Cancer Care

March 10th 2024

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

Dr Tripathy on the Management of Early-Stage HER2+ Breast Cancer

March 10th 2024

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.

HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

March 10th 2024

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Dr Rugo on the Evolution of ADCs in HR+/HER2+ and HER2-Low Breast Cancer

March 9th 2024

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.

Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena

March 9th 2024

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC

March 9th 2024

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation

March 8th 2024

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.

PRMT5 Inhibitors Plus Antiestrogens May Combat Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer

March 8th 2024

PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.

ADCs Serve as “Exciting and Effective Drug Delivery System” in HR+/HER2– Breast Cancer

March 8th 2024

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.

Racial Disparities Magnified in Cardiac Dose, Toxicity Differences With RT for Breast Cancer

March 8th 2024

Racial and ethnic disparities for mortality are present in breast cancer, especially as it relates to radiation therapy toxicity and cardiac dose.